
    
      Part I (Phase I) of the study enrolls patients with advanced solid tumors (9-15 patients);
      Part II (Phase II) of the study enrolls patients with urothelial carcinoma or
      cholangiocarcinoma with FGFR genetic alterations (30 patients).
    
  